Quantcast

Latest Steatohepatitis Stories

2014-07-21 10:59:26

Massachusetts General Hospital Daily treatment with tesamorelin for six months lowered liver fat modestly but significantly The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. In a paper that will appear in the July 23/28 issue of JAMA – a theme issue on HIV/AIDS receiving early online release to coincide with...

2014-07-08 12:28:47

TEL AVIV, Israel, July 8, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial manuscript, entitled "The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease," provides the full report of the Phase IIa trial, which was...

2014-07-01 16:29:45

NY Times Article Brings Attention to Dangerous Lifestyle Related Epidemic and Suggests Critical Need for Therapy DENVER, July 1, 2014 /PRNewswire/ -- A recent New York Times article ("Threat Grows from Liver Illness Tied to Obesity", June 13 2014) alerting millions to the growing prevalence and seriousness of fatty liver disease revealed a stark and very concerning reality about therapeutic options. There are currently no drugs approved for either NAFLD (nonalcoholic fatty liver...

2014-06-30 16:26:43

SOUTH SAN FRANCISCO, June 30, 2014 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today that it has closed a four year, $15 million term loan facility with Oxford Finance LLC. The facility will support the development of CVC for the treatment of nonalcoholic steatohepatitis (NASH) and for working capital and general corporate needs. About Tobira Therapeutics Tobira Therapeutics is...

2014-06-23 08:28:45

Company Presents Positive Preclinical Efficacy Results at ICE/ENDO 2014 Meeting RALEIGH, N.C., June 23, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin),...

2014-06-18 08:28:52

RALEIGH, N.C., June 18, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine...

2014-05-12 08:31:08

DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease pipeline assets - Adds to Shire's rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire's already strong Gastrointestinal (GI) presence - Adds LUM001 in Phase 2 development for four rare and devastating hepatic diseases, two...

2014-03-22 23:03:03

ReportsnReports.com offers "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" 2014 market research report in its store. Dallas, TX (PRWEB) March 22, 2014 OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update report estimates the 2012 off-label sales for nonalcoholic steatohepatitis (NASH) to be approximately $233m across the US and five...

2014-03-11 08:29:53

Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. New Enterprise Associates (NEA) led the financing,...

2014-02-26 16:25:07

LONDON, Feb. 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022SummaryNonalcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease, but occurs in people who drink...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related